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ABSTRACT  
Objective: The main objective of this research work was to formulate and evaluate the mouth dissolving tablet of amlodipine besylate for the 
treatment of hypertension and coronary artery disease. 
Methods: In this study, mouth dissolving tablet were prepared by direct compression method by using croscarmellose sodium and sodium starch 
glycolate as superdisintegrants. The designed tablets were subjected to various assessment parameters like friability test, hardness test, 
disintegration test, wetting time, in vitro drug release and drug content. 
Results: All the prepared formulations were subjected to various assessment parameters, and the findings obtain within the prescribed limit. The 
calibration curve of pure drug using various solvents like phosphate buffer pH 6.8, methanol was plotted. F1-F9 containing croscarmellose sodium 
and sodium starch glycolate in various concentration demonstrate the minimum disintegration time. Among all these formulations F9 shows 
disintegration time up to 22±1.12 seconds due to the high concentration of superdisintegrants. In vitro drug release was tested in phosphate buffer 
pH 6.8 at a time interval of 0, 1, 2, 3, 4, 5 min. The F9 shows drug release 100.22±1.08%. Accelerated stability study of optimized formulation (F9) 
up to 2 mo showed there was no change in disintegration time and percentage drug release.  
Conclusion: The results obtained in the research work clearly showed a promising potential of mouth dissolving tablets containing a specific ratio 
of croscarmellose sodium and sodium starch glycolate as superdisintegrants for the effective treatment of hypertension and coronary artery 
disease. 
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Oral route of drug administration has wide acceptance of up to 50-
60% of total dosage forms. Solid dosage forms are popular because 
of ease of administration, accurate dosage, self-medication, pain 
avoidance and most importantly the patient compliance. The most 
popular solid dosage forms are being tablets and capsules, one 
important drawback of this dosage form for some patients is the 
difficulty to swallow. Mouth dissolving tablets provide an advantage, 
particularly for pediatric and geriatric populations who have 
difficulty in swallowing conventional tablets and capsules. Mouth 
dissolving of tablet results in quick dissolution and rapid absorption, 
which provide rapid onset of action. Morever, drug candidates that 
undergoes pre-gastric absorption when formulated as mouth 
dissolving tablets may show increased oral bioavailability. It 
provides good stability, accurate dosing, easy manufacturing. Angina 
pectoris is chest pain due to ischemia of heart muscle due to 
obstruction or spasm of the coronary arteries. Amlodipine besylate 
is a long-acting calcium channel blocker mainly used in the 
treatment of chronic stable angina vasospastic angina and 
hypertension. It inhibits the transmembrane influx of calcium ion 
into vascular smooth muscle and cardiac muscle. Peak plasma 
concentrations are reached 6-12 h. It has an oral bioavailability of 
64-90% and half-life of about 30-50 h. Amlodipine besylate is a 
slightly soluble drug the rate of absorption is controlled by the rate 
of dissolution. The rate of dissolution can be increased by the use of 
super disintegrants. Mouth dissolving tablets are designed to be 
placed in mouth allowed to dissolve in the saliva and then 
swallowed without the aid of water. The objective of the present 
study was to deliver the drug at a faster rate and to provide 
immediate onset of action in a shorter period of time with improved 
bioavailability. The basic approach in the development of oral 
disintegrating tablets is the use of superdisintegrants like 
croscarmellose sodium, sodium starch glycolate [1-10]. 
MATERIALS AND METHODS  
Materials  
Amlodipine besylate procured from Blue cross Pvt. Ltd., Nashik. All 
the other reagents used were of analytical grade. 
Methods 
Determination of λ max of amlodipine besylate 
The UV spectrum of amlodipine besylate was obtained by using a 
UV-visible spectrometer (UV-2450, Shimadzu). Accurately weigh 10 
mg of the drug was added to 100 ml of volumetric flask. Volume was 
made up to 100 ml with water (100 μg/ml). This solution was used 
as a stock solution. From this solution (100 μg/ml) suitable working 
solutions of different concentrations of 10, 20, 30, 140, and 50 μg/ml 
were prepared. The resultant solution was scanned from 400 to 200 
nm, and the spectrum was recorded to obtain the value of the 
maximum wavelength in the respective solvents. The absorbance of 
each standard solution was determined spectrophotometrically. 
Using absorbance concentration data, Beer-Lambert’s plot was 
constructed [11]. 
Drug excipients compatibility study Infrared spectrum  
The infrared (IR) spectrum of amlodipine besylate was recorded 
with potassium bromide (KBr) discover the wave number of 4000 to 
400 cm-1
Formulation of mouth dissolving tablets 
by using fourier transform infrared spectrophotometer 
(FTIR) [12]. 
Direct compression method was followed to manufacture tablets for 
all batches. Amlodipine besylate, sodium starch glycolate, 
croscarmellose sodium, d-Mannitol, microcrystalline cellulose, 
magnesium stearate, saccharine sodium, were passed through #690 
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sieves. Weighed amounts of the drug as well as all other ingredients 
were transferred to mortar and blended for 15 min with the help of 
pestle. The accurately weighed quantity for one tablet was poured in 
die cavity. Tablet thickness and hardness were adjusted with the 
help of thickness adjustment screw and compression pressure 
adjustment knob respectively. Powder filled in die cavity was 
subjected to compression using 10-station rotary press using round 
shaped concave punches measuring 8 mm diameter. Collected 
tablets were de-dusted and subjected to further evaluation 
parametes [13]. 
Formulation optimization 
The 3² full factorial design was adopted for formulation purpose. 
The amount of superdisintegrants, sodium starch glycolate (X₁) and 
croscarmellose sodium (X₂) were taken as independent variables. 
The factors were studied at tree levels (-1, 0, +1) indicating low, 
medium and high, respectively. The statistical optimization 
procedure was performed with the help of optimization software 
design expert 8.0.4 (Stat-Ease Inc. MN, USA). The software performs 
an analysis of variance and statistical optimization. 
 
Table 1: Independent variables 
Factor level Coded form Actual value (mg) Predicted value (mg) 
X₁ X₂ X₁ X₂ 
Low -1 2 1 1 0.5 
Medium  0 5 3 2.5 1.5 
High +1 8 5 4 2.5 
 
Table 2: Composition of mouth dissolving tablet of amlodipine besylate 
Ingredients (mg/tablets) F1 F2 F3 F4 F5 F6 F7 F8 F9 
amlodipine besylate 10 10 10 10 10 10 10 10 10 
Croscarmellose sodium 1 3 5 1 3 5 1 3 5 
sodium starch glycolate 2 2 2 5 5 5 8 8 8 
d-mannitol 40 40 40 40 40 40 40 40 40 
microcrystalline cellulose 93 91 89 90 88 86 87 85 83 
saccharin sodium 1 1 1 1 1 1 1 1 1 
magnesium stearate 3 3 3 3 3 3 3 3 3 
total 150 150 150 150 150 150 150 150 150 
 
Evaluation  
Precompression parameters  
Angle of repose (θ)  
Angle of repose is defined as the maximum angle possible between 
the surface of a pile of the powder and horizontal plane. The 
frictional force in loose powder or granules can be measured by the 





Where θ = angle of repose,  
h = height of the pile,  
r = radius of the pile base 
Bulk density 
The bulk density of a powder is dependent on particle packing and 
changes as the powder consolidate. Apparent bulk density was 
determined by pouring the bulk powder into a graduated cylinder 
via a large funnel and measuring the volume and weight. Bulk 






Tapped density is the bulk density of a powder which has been 
compacted by tapping or vibration. Tapped density was determined 
by placing a graduated cylinder containing a known mass of powder 
on a mechanical tapping apparatus, which is operated for a fixed 
number of taps (100) or until the powder bed volume has reached a 
minimum. The tapped density was computed by taking the weight of 






Hausner’s ratio is an indirect index of ease of powder flow. It is 
calculated by the following formula [14]. 
Hausner′s ratio =
tapped density of powder
bulk density of powder
 
Compressibility Index (Carr’s Index) 
Another indirect method of measuring powder flow from bulk 
densities was developed by Carr’s. The percentage compressibility 
of a powder is a direct measure of the potential powder arch or 
bridge strength and stability. It is calculated according to the 
following equation [14]. 
Carr′s index =
(tapped density − bulk density)
tapped density
 x 100 
Weight variation test 
Twenty tablets were selected randomly from each batch and 
weighed individually in electronic balance (shimadzu). The Indian 
pharmacopeia allows a little variation in the weight of a tablet. 
Average weight was calculated, and the standard deviation was 
computed. Average of 20 readings is taken [14]. 
Uniformity of thickness  
The thickness of individual tablet may be measured with a digital 
vernier caliper, which permits accurate measurements and provides 
information on the variation between tablets. Averages of triplicate 
readings were taken [14]. 
Hardness test 
The strength of the tablet is expressed as tensile strength (Kg/cm2
Friability  
). 
The tablet crushing load, which is the force required to break a 
tablet into pieces by compression. It was measured using a tablet 
hardness tester (Monsanto hardness tester). Three tablets from each 
formulation batch were tested randomly and the average readings 
were noted [15, 16]. 
Friability of the tablets was determined using roche friabilator. This 
device consists of a plastic chamber that is set to revolve around 25 
RPM for 4 min dropping the tablets at a distance of 6 inches with 
each revolution. Pre-weighed a sample of 20 tablets was placed in 
the friabilator and was subjected to 100 revolutions. Tablets were 
dusted using a soft muslin cloth and reweighed. The friability (F %) 
was then calculated by [15, 16]. 
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(original weight − weight after 100 revoluations)
original weight
 x 100 
Drug content 
Twenty tablets from each batch were weighed accurately and 
powdered. Weight the quantity of the powder equivalent to 100 mg 
of amlodipine besylate, and was shaken with 100 ml of distilled 
water in 100 ml volumetric flask. From this 10 ml was pipette out 
and diluted upto 100 ml with distilled water. From this solution 
again 10 ml pipette out and diluted up to 100 ml in 100 ml 
volumetric flask. Resulting solution was filtered and absorbance was 
checked at 239 nm and content of amlodipine besylate was 
calculated using distilled water as a blank [17]. 
Wetting time 
A piece of tissue paper (12 cm x 10.75 cm) folded twice was placed 
in a petri dish (internal diameter=9 cm) containing 9 ml of buffer 
solution, which had the following to the petri dish. A tablet was 
carefully placed on the surface of tissue paper. The time required for 
water to reach the upper surface of the tablets was noted as the 
wetting time. Six tablets from each formulation batch were tested 
randomly and the average reading noted [18]. 
Water absorption ratio  
A petri dish with an inner diameter of 6.5 cm and having 6 ml water 
in it was used for this test. A tissue paper folded twice was put in the 
petri dish. A pre-weighed tablet was positioned on it, after complete 
wetting the tablet was re-weighed [19]. 
R =
Wa
Wb  x 100 
R= water absorption ratio 
Wa= weight of tablet after wetting 
Wb= weight of the tablet before wetting 
In vitro disintegration time  
Disintegration time for mouth dissolving tablets was determined using 
USP disintegration apparatus with phosphate buffer of pH 6.8. The 
volume of the medium was 900 ml and the temperature was 37 °C±2 
°C. The time in seconds taken for the complete disintegration of the 
tablet with no palatable mass remaining on the mesh was measured. 
To comply the test, all tablets should disintegrate within 3 min [18]. 
In vitro drug release studies 
To study the drug release from the tablet, the USP type II (paddle) 
apparatus was employed. In this method, 900 ml of phosphate buffer 
pH 6.8 was used as the dissolution media and the paddle was 
rotated at a constant speed of 500 rpm. The temperature of the 
medium was maintained at 37 °C±0.5 °C. Sample of 5 ml was 
removed at an interval of one minute for 7 min. The sample were 
filtered and the concentration in each sample was determined by UV 
spectrophotometer and reported as an average of three 
determinations [20-24, 26]. 
Stability study  
Stability study was conducted as per ICH guidelines 40 °C±2 °C, 
75%±2% RH to test the chemical and physical stability of fast 
dissolving tablets for the period of 2 mo [25]. 
RESULTS AND DISCUSSION  
Determination of λ max of amlodipine besylate  
λ max of amlodipine besylate was determined in methanol. The 
calibration curve of amlodipine besylate shown linearity as per 
Beers Lambert’s law at 239 nm represented in fig. 1. 
 
 
Fig. 1: Calibration curve of amlodipine besylate in methanol 
 
Drug excipients compatibility study IR spectrometer study  
The IR spectra of amlodipine besylate, polymers, and physical 
mixture are shown in fig. The IR absorption bands observed in the IR 
spectrum of drug and polymers resembles with that of found in 
physical mixture proves the compatibility of the drug with polymers. 
The fig. 3 shows absorption spectrum of drug and croscarmellose 
sodium and fig. 4 shows an absorption spectrum of drug and sodium 
starch glycolate [28]. 
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Fig. 2: FTIR of amlodipine besylate 
 
 
Fig. 3: FTIR spectra of drug and drug+croscarmelose sodium 
 
 
Fig. 4: FTIR spectra of drug and drug+sodiumstarch glycolate 
 
 
Fig. 5: FTIR spectra of drug and drug+mixture 
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Differential scanning colorimetry (DSC)  
Thermal analysis of drugs carried out using DSC. The DSC curve of 
amlodipine besylate profiles a sharp exothermic peak at 106.53 °C 
corrosponding to it’s melting, and indicating it’s crystalline nature 




Fig. 6: DSC of amlodipine besylate 
 
The thermogram of drug and tablet mixture showed matching peaks. 
The characteristic exothermic peak of the drug was also present in 
the spectra of the drug-tablet mixture. Overlay spectra of drug with 
the total mixture is shown in fig. 7. 
 
 
Fig. 7: DSC of drug+mixture 
 
Precompression evaluation parameters of powder 
Angle of repose  
The angle of repose is an inactive parameter of powder flowability 
from the hopper to die cavity. An angle of repose between 25 ° to 30 ° 
indicates excellent flowability of the powder bed. In this work, the 
angle of repose was found to be varying between 25.40 °-29.76 ° when 
glidants were incorporated. These studies indicated that the powder 
beds of all formulations are easily flow able. All the precompression 
parameters were found to be within the acceptable limit.  
Bulk density  
Bulk density was found in the range of 0.273±0.0030 to 
0.378±0.0055 g/ml.  
 
Table 3: Precompression parameters for fast dissolving tablets of F1 to F9 
Formulation code *
( °)  




Tapped density (g/ml)  Compressibility index (%) Hausner’s ratio 
F1 26.91±0.021 0.378±0.0055 0.440±0.0061 14.12±2.26 1.079 
F2 28.02±0.017 0.353±0.0028 0.400±0.0050 11.17±0.532 1.132 
F3 27.19±0.031 0.325±0.0087 0.393±0.0057 17.16±3.38 1.206 
F4 25.99±0.075 0.373±0.0065 0.393±0.0073 12.25±2.97 1.139 
F5 29.76±0.023 0.329±0.0028 0.425±0.006 13.45±2.05 1.155 
F6 29.20±0.051 0.314±0.002 0.381±0.0096 8.40±2.257 1.086 
F7 25.40±0.040 0.296±0.0037 0.343±0.0070 7.56±1.100 1.073 
F8 26.90±0.025 0.273±0.0030 0.304±0.0063 10.03±2.875 1.108 
F9 26.75±0.020 0.295±0.0015 0.322±0.0061 8.44±2.219 1.091 
*All the values are expressed as mean±SD, where n=3, SD: Standard deviation 
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Tapped density  
Tapped density was found to be in the range of 0.304±0.0063 to 
0.440±0.0061 g/ml.  
Percentage compressibility index  
Compressibility index was found to be in the range of 7.56 % to17.16 %. 
All formulations showed good flow properties which are given in table 3. 
Hausner’s ratio  
Hausner’s ratio was found to be in the range of 1.073 to 1.206 [24]. 
Post-compression evaluation of fast dissolving tablets of 
amlodipine besylate 
Thickness  
The thickness of the tablets was found to be uniform, between 
2.21±0.005 mm to 2.29±0.005 mm for (F1 to F9).  
Hardness  
The hardness of the tablets varied between 2.89±0.036 Kg/cm2to 
3.78±0.047Kg/cm2
The % friability was found in the range of 0.44±0.05% to 
0.88±0.06% which passes standard.  
indicating good binding and satisfactory strength 
of tablets to withstand stresses during transportation and also may 
offer good dissolution property.  
% Friability  
Weight variation  
The weight of the formulated tablets of amlodipine besylate (F1 to 
F9) was found to be uniform with low standard deviation values 
from 148.96±1.35 to 150.56±1.44 mg. The prepared formulations 
comply with the weight variation test as per IP. The results are given 
in table 4.  
Water absorption ratio 
The water absorption ratio ranged from 95.33±0.67 to 100.89±1.01. 
All the formulations pass the test as per IP standards [24]. 
Wetting time  
It is the time required for complete wetting of tablet. The wetting 
time was found in the range of 15±0.56 to 31±0.89 sec.  
Disintegration time  
It is the time required for complete disintegration of the tablet. The 
disintegration time was found in the range of 22±1.12 to 35±1.84 
sec.  
Drug content  
Drug content found in the fast dissolving tablets resembling that of 
literature value. Range of drug content is 95.16%-101.28%. 
Therefore uniformity of content was maintained in all formulations. 
Drug content of all formulations is listed in table 4. [24]. 
 













 %  Average weight 
Mg (mean±SD)  
Water absorption ratio 
F1 2.21±0.005 3.46±0.028 0.62±0.05 149.1±1.04 98.21±1.389 
F2 2.25±0.01 3.14±0.128 0.58±0.03 149.3±1.84 100.89±1.01 
F3 2.26±0.032 3.78±0.047 0.58±0.08 148.96±1.35 97.99±0.665 
F4 2.29±0.005 3.38±0.047 0.55±0.06 150.56±1.44 99.3±0.10 
F5 2.22±0.015 3.63±0.015 0.54±0.08 149.16±0.93 96.44±0.38 
F6 2.22±0.015 2.95±0.046 0.45±0.06 149.1±1.04 97.29±0.28 
F7 2.22±0.01 3.15±0.132 059±0.02 149.34±0.87 99.99±1.32 
F8 2.23±0.115 2.89±0.036 0.44±0.05 150.1±1.31 95.33±0.67 
F9 2.25±0.01 3.22±0.0023 0.88±0.06 150.19±1.10 96.6±0.38 
*All the values are expressed as mean±SD, where n=20 and # n=3  
 
Table 5: Post compression parameters for mouth dissolving tablets of F1 to F9 
Formulation code Wetting time*(Sec) (mean±SD)  Disintegration time (Sec) 
(mean±SD)  
Drug content  
(%) (mean±SD)  
F1 20±0.88 25±1.76 98.11±0.56 
F2 22±0.67 28±1.34 96.20±0.96 
F3 31±0.89 35±1.84 101.28±1.25 
F4 21±0.87 26±1.36 99.3±0.45 
F5 27±0.98 32±1.25 97.2±0.65 
F6 22±0.32 28±1.45 95.16±1.56 
F7 28±0.77 34±1.69 97.46±1.69 
F8 18±0.65 24±1.77 98.86±0.87 
F9 15±0.56 22±1.12 99.24±0.26 
All the values are expressed as mean±SD, SD: Standard deviation, where* n=3.  
 
% cumulative drug release of the different formulations is shown 
in fig. 4. In this formulations as the level of croscarmellose 
sodium and sodium starch glycolate is increased the drug release 
will also increases. Release of the drug in vitro, was determined 
by estimating the dissolution profile, USP 2 paddle apparatus 
was used and the paddle was allowed to rotate at 50 rpm, 
phosphate buffer (pH 6.8) (900 ml) was used as a dissolution 
medium [28]. 
% cumulative drug release  
% cumulative drug release was found in the range of 90.57±0.99 to 
99.65±0.63%.
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Fig. 8: Graph of %drug release of mouth dissolving tablet of amlodipine besylate 
 
Table 6: Stability study of the optimized formulation 
S. No. Observations Before stability 
*(mean±SD) 
Stability testing interval days  
1 mo *(mean±SD) 2 mo *(mean±SD) 
1 Visual Appearance White White White 
2 disintegration time(sec) 22±1.12 22±1.35 23±1.54 
3 drug content 99.24±0.26 99.50±0.26 100.25±0.26 
*All values are mean±SD, SD: Standard deviation, where* n=3 
 
Stability study  
Results of the stability studies showed that there is no change in the 
physical parameters of the formulation. Drug content of the 
formulation was also found to be same as that before stability 
testing. Stability data is shown in table 6. 
CONCLUSION  
The current studies are aimed at successful development and 
optimization of the mouth dissolving tablet of amlodipine besylate 
and to enhance the bioavailability of the drug by avoiding first 
pass effect. Among the prepared batches of tablets based on 
performance with respect to friability, hardness, uniformity of 
drug content, disintegration and in vitro drug release studies, F9 
delivers the best results as compared to other formulations. Thus, 
drug release from the mouth dissolving tablet was increased by 
using the increased concentration of superdisintegrants, assisting 
in faster disintegration in the oral cavity. As the drug having fast 
disintegration may leads to more drug availability for dissolution, 
resulting in faster absorption and possibly bioavailability leads to 
the quick onset of action in the systemic circulation.  
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